Its important for patients to understand that GLP-1 medications are not a skinny shot, but a tool designed to support metabolic health through long-term weight management
FDA approval in 2026 is considered unlikely (prediction markets put it at ~27%)
Retatrutide has produced large average weight-loss results in published obesity research, while tirzepatide has shown large average reductions in pivotal studies used for approval decisions
Reconstituted clear with no particulates, exactly as the certificate describes, and the lot number on the vial matched the COA online
This page summarises the published preclinical and clinical research behind retatrutide and explains how the compound is characterised, stored and handled in a research setting
Get access to step-by-step management algorithms, the latest research, and peer-reviewed insightsall in one place